TL;DR: Aetna, a CVS Health company, modified CPB 0528 governing testosterone undecanoate (Aveed) injection coverage, effective September 26, 2025. Here's what billing teams need to act on before claims start hitting denials.
Aetna updated its testosterone undecanoate coverage policy under CPB 0528 Aetna system, covering HCPCS code J3145 (injection, testosterone undecanoate, 1 mg) alongside supporting CPT codes 84402, 84403, and 84410 for testosterone lab testing. This policy applies to commercial medical plans — Medicare criteria live separately. If your practice bills Aveed injections, precertification is mandatory, and the wrong ICD-10 code will kill your claim before it gets reviewed.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Testosterone Undecanoate (Aveed) Injection |
| Policy Code | CPB 0528 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | Urology, Endocrinology, Primary Care, Internal Medicine, Gender-Affirming Care, Home Health |
| Key Action | Confirm precertification is in place for J3145 before billing; verify ICD-10 code is on the covered list |
Aetna Testosterone Undecanoate Coverage Criteria and Medical Necessity Requirements 2025
The Aetna testosterone undecanoate coverage policy under CPB 0528 requires precertification for every claim. No exceptions. Call (866) 752-7021 or fax (888) 267-3277 to get it done. For Statement of Medical Necessity (SMN) forms, go to Aetna's Specialty Pharmacy Precertification page directly — don't use generic prior authorization forms.
Medical necessity is the hinge this policy swings on. Aetna will cover testosterone undecanoate injection (J3145) when the diagnosis maps to a recognized disease state. The covered ICD-10 codes tell you exactly which conditions qualify — and they're more specific than you might expect.
Hypogonadotropic hypogonadism (E23.0) is covered. Testicular hypofunction (E29.1) has a direct carve-out: Aetna explicitly excludes age-related hypogonadism under this code. That's a claim denial waiting to happen if your provider documents "low T" without a specific underlying cause.
The policy also covers gender identity disorder diagnoses across F64.0 through F64.9, which is a broad range. Document the specific gender dysphoria diagnosis from the F64 range on every claim — don't just bill F64.9 by default. The more specific the code, the cleaner the medical necessity argument.
For reimbursement purposes, Aveed is a long-acting injectable. Most plans price J3145 per 1 mg. A full 750 mg dose means billing J3145 x 750 units. Confirm your unit billing is correct before submission — underbilling here is a real revenue leak.
Aetna Testosterone Undecanoate Exclusions and Non-Covered Indications
This section is where Aetna gets direct, and your billing team needs to take it seriously.
Performance enhancement is categorically excluded. Aetna states that plans without a specific steroid exclusion still won't cover testosterone for performance enhancement. The rationale: enhancing function in non-diseased individuals isn't treatment of disease or injury. If your provider documents anything that reads like fatigue management, athletic recovery, or general wellness, expect a denial.
Age-related hypogonadism is explicitly not covered under E29.1. This is one of the sharpest edges in this policy. A patient with low testosterone due to aging — without a documented underlying pathological cause — doesn't meet medical necessity under CPB 0528. Cognitive decline in aging men (R41.81) is also listed, but it's in the non-covered category. Don't bill J3145 for a diagnosis of age-related cognitive decline expecting payment.
The improvement of cognitive function in aging men is not a covered indication. Full stop. If that's in the note, the claim won't clear medical necessity review.
Check your benefit plan descriptions for the steroid exclusion language. Some commercial plans add it explicitly. If your patient's plan has that exclusion, prior authorization won't save you — the coverage policy itself closes the door.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Hypogonadotropic hypogonadism | Covered | E23.0, J3145 | Precertification required |
| Testicular hypofunction (pathological cause) | Covered | E29.1, J3145 | Age-related hypogonadism specifically excluded |
| Age-related hypogonadism | Not Covered | E29.1 | Explicitly excluded |
| Gender identity disorders | Covered | F64.0–F64.9, J3145 | Use most specific F64 code; precertification required |
| Hypoactive sexual desire disorder | Covered | F52.0, J3145 | Precertification required |
| Female sexual arousal disorder | Covered | F52.22, J3145 | Precertification required |
| Menopausal and perimenopausal disorders | Covered | N95.0–N95.9, J3145 | Precertification required |
| Amyotrophic lateral sclerosis | Covered | G12.21, J3145 | Precertification required |
| Heart failure | Covered | I50.1–I50.9, J3145 | Precertification required |
| Performance enhancement | Not Covered | — | Excluded regardless of plan steroid exclusion language |
| Age-related cognitive decline / cognitive improvement in aging men | Not Covered | R41.81 | Explicitly excluded |
Aetna Testosterone Undecanoate Billing Guidelines and Action Items 2025
The effective date is September 26, 2025. If you're billing J3145 now, these steps apply immediately.
| # | Action Item |
|---|---|
| 1 | Confirm precertification is active for every J3145 claim. Call (866) 752-7021 or fax the SMN form to (888) 267-3277 before the injection is administered. Billing without prior authorization means a clean denial with no appeal path. |
| 2 | Audit your ICD-10 codes against the covered list before September 26, 2025. Pull your last 90 days of Aveed claims. Check every primary diagnosis against the covered indications above. If you see E29.1 with no documented pathological cause — or R41.81 as a primary — flag those charts for physician review before the modified policy is fully in effect. |
| 3 | Update your charge capture for J3145 unit billing. Aveed is dosed at 750 mg. J3145 is billed per 1 mg. Bill J3145 x 750 units per injection. If your system defaults to x1, you're leaving significant reimbursement on the table with every claim. |
| 4 | Add CPT 96372 to injection encounter claims correctly. CPT 96372 covers the therapeutic intramuscular injection administration. Bill it alongside J3145 when your staff administers the injection in-office. Don't bill 96372 without the drug code, and don't bill the drug code without the administration code. |
| 5 | Flag home injection visits for CPT 99506. If your practice or a home health agency administers Aveed at home, CPT 99506 (home visit for intramuscular injection) is the correct code. Make sure your billing team isn't using 99506 for in-office visits — it's specifically for home administration. |
| 6 | Order the right testosterone labs and code them correctly. Aetna's coverage policy ties medical necessity documentation to testosterone testing. Use CPT 84403 for total testosterone, 84402 for free testosterone, and 84410 for bioavailable testosterone. SHBG testing bills under CPT 84270. If your provider orders the HCG stimulation panel for diagnosis, that's CPT 80414. These labs support your medical necessity documentation — don't skip them. |
| 7 | Separate Medicare patients from commercial patients in your workflow. CPB 0528 applies to commercial plans only. Medicare criteria are handled separately. If your billing team uses the same workflow for both, you'll end up applying the wrong precertification process. Build a payer check into your intake workflow now. |
| 8 | Talk to your compliance officer if your patient mix includes gender-affirming care. The F64.0–F64.9 codes are covered, but plan-level exclusions vary. Some self-funded commercial plans opt out of gender-affirming care coverage. Your compliance officer should review your specific plan contracts before you assume coverage applies. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Testosterone Undecanoate Under CPB 0528
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J3145 | HCPCS | Injection, testosterone undecanoate, 1 mg |
Supporting CPT Codes Related to CPB 0528
| Code | Type | Description |
|---|---|---|
| 80414 | CPT | Chorionic gonadotropin stimulation panel; testosterone response |
| 84270 | CPT | Sex hormone binding globulin (SHBG) |
| 84402 | CPT | Testosterone; free |
| 84403 | CPT | Testosterone; total |
| 84410 | CPT | Testosterone; bioavailable, direct measurement (e.g., differential precipitation) |
| 96372 | CPT | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
| 99506 | CPT | Home visit for intramuscular injection |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| E23.0 | Hypopituitarism [hypogonadotropic hypogonadism] |
| E29.1 | Testicular hypofunction [not covered for age-related hypogonadism] |
| F52.0 | Hypoactive sexual desire disorder |
| F52.22 | Female sexual arousal disorder |
| F64.0 | Gender identity disorders |
| F64.1 | Gender identity disorders |
| F64.2 | Gender identity disorders |
| F64.3 | Gender identity disorders |
| F64.4 | Gender identity disorders |
| F64.5 | Gender identity disorders |
| F64.6 | Gender identity disorders |
| F64.7 | Gender identity disorders |
| F64.8 | Gender identity disorders |
| F64.9 | Gender identity disorders |
| G12.21 | Amyotrophic lateral sclerosis |
| I50.1 | Heart failure |
| I50.2 | Heart failure |
| I50.3 | Heart failure |
| I50.4 | Heart failure |
| I50.5 | Heart failure |
| I50.6 | Heart failure |
| I50.7 | Heart failure |
| I50.8 | Heart failure |
| I50.9 | Heart failure |
| N95.0 | Menopausal and other perimenopausal disorders |
| N95.1 | Menopausal and other perimenopausal disorders |
| N95.2 | Menopausal and other perimenopausal disorders |
| N95.3 | Menopausal and other perimenopausal disorders |
| N95.4 | Menopausal and other perimenopausal disorders |
| N95.5 | Menopausal and other perimenopausal disorders |
| N95.6 | Menopausal and other perimenopausal disorders |
| N95.7 | Menopausal and other perimenopausal disorders |
| N95.8 | Menopausal and other perimenopausal disorders |
| N95.9 | Menopausal and other perimenopausal disorders |
| R41.81 | Age-related cognitive decline [improvement of cognitive function in aging men — not covered] |
Get the Full Picture for CPT 96372
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.